Beta-cell dysfunction and impaired insulin production are hallmarks of diabetes 1 , but despite the growing diabetes epidemic, the molecular mechanisms underlying this disease have remained unclear. We identified thioredoxin-interacting protein (TXNIP), a cellular redox regulator, as a crucial factor in beta-cell biology and show that beta-cell TXNIP is upregulated in diabetes, whereas TXNIP deficiency protects against diabetes by preventing beta-cell apoptosis 2,3 . Here we show that TXNIP and diabetes induce beta-cell expression of a specific microRNA, miR-204, which in turn blocks insulin production by directly targeting and downregulating MAFA, a known insulin transcription factor. In particular, we first discovered the regulation of miR-204 by TXNIP by microarray analysis, followed by validation studies in INS-1 beta cells, islets of Txnip-deficient mice, diabetic mouse models and primary human islets. We then further found that TXNIP induces miR-204 by inhibiting the activity of signal transducer and activator of transcription 3 (STAT3), a transcription factor that is involved in miR-204 regulation 4,5 . We also identified MAFA as a target that is downregulated by miR-204. Taken together, our results demonstrate that TXNIP controls microRNA expression and insulin production and that miR-204 is involved in beta-cell function. The newly identified TXNIP-miR-204-MAFA-insulin pathway may contribute to diabetes progression and provides new insight into TXNIP function and microRNA biology in health and disease.
l e t t e r S Beta-cell dysfunction and impaired insulin production are hallmarks of diabetes 1 , but despite the growing diabetes epidemic, the molecular mechanisms underlying this disease have remained unclear. We identified thioredoxin-interacting protein (TXNIP), a cellular redox regulator, as a crucial factor in beta-cell biology and show that beta-cell TXNIP is upregulated in diabetes, whereas TXNIP deficiency protects against diabetes by preventing beta-cell apoptosis 2, 3 . Here we show that TXNIP and diabetes induce beta-cell expression of a specific microRNA, miR-204, which in turn blocks insulin production by directly targeting and downregulating MAFA, a known insulin transcription factor. In particular, we first discovered the regulation of miR-204 by TXNIP by microarray analysis, followed by validation studies in INS-1 beta cells, islets of Txnip-deficient mice, diabetic mouse models and primary human islets. We then further found that TXNIP induces miR-204 by inhibiting the activity of signal transducer and activator of transcription 3 (STAT3), a transcription factor that is involved in miR-204 regulation 4, 5 . We also identified MAFA as a target that is downregulated by miR-204. Taken together, our results demonstrate that TXNIP controls microRNA expression and insulin production and that miR-204 is involved in beta-cell function. The newly identified TXNIP-miR-204-MAFA-insulin pathway may contribute to diabetes progression and provides new insight into TXNIP function and microRNA biology in health and disease.
Production and release of adequate amounts of insulin by pancreatic beta cells is a prerequisite for maintaining normal glucose homeo stasis. Indeed, betacell dysfunction and impaired insulin produc tion are key factors in the pathogenesis of diabetes 1 , but despite the growing worldwide diabetes epidemic, the molecular mechanisms involved in this disease process have only begun to be discovered. Recently we identified TXNIP, a cellular redox regulator 6 , as a crucial factor in betacell biology. In particular, we previously showed that betacell TXNIP was upregulated in diabetes, whereas TXNIP defi ciency protected against type 1 and type 2 diabetes by preventing beta cell apoptosis and increasing wholepancreas betacell mass 2, 3, [7] [8] [9] [10] [11] . Furthermore, we revealed the pathways by which TXNIP induces apoptosis 2, 10 and discovered that TXNIP shuttles within the beta cell and translocates from the nucleus into the mitochondria, where it initiates the mitochondrial apoptotic cascade 10 . The discovery that under normal conditions TXNIP is localized primarily in the nucleus combined with our previous gene expression profiling studies demonstrating that ~95% of all altered genes are downregulated by TXNIP 9 raised the possibility that TXNIP might be involved in the control (particularly the inhibition) of betacell gene expression, which prompted us to study the potential effects of TXNIP on micro RNA expression.
MicroRNAs (small 20 to 24nt noncoding RNAs) recognize and bind target mRNAs through imperfect base pairing, which leads to mRNA degradation or translational inhibition of the target mRNA and downregulation of target gene expression [12] [13] [14] . MicroRNAs are rapidly emerging as important regulators of gene expression in health and disease and were also recently discovered to have various roles in diabetes and betacell biology [15] [16] [17] [18] [19] [20] [21] .
Comparison of our TXNIPoverexpressing INS1 betacell line (INSTXNIP) and a control INS1 betacell line expressing LacZ (INSLacZ) using miRCURY LNA microRNA Arrays (Exiqon) and an absolute difference threshold of 0.7 in LogMedianRatio (1.6fold change) revealed five microRNAs (miR1395p, miR193, miR204, miR200c and miR141) that were upregulated in response to TXNIP overexpression (Supplementary Table 1 ). After confirming these findings by quantitative realtime PCR, we investigated the role of these microRNAs by systematically knocking them down using spe cific inhibitor oligonucleotides and assessing the effects on insulin production, a key aspect of betacell function. However, only knock down of miR204 had a significant (P < 0.05) effect and led to an increase in insulin expression. Moreover, only overexpression of miR204, but not any of the other microRNAs, resulted in a marked decrease in insulin mRNA expression (Supplementary Fig. 1a) .
Notably, miR204 (which is fully conserved between human, rat and mouse) (Supplementary Fig. 1b) has not been implicated in betacell biology but is highly expressed in insulinomas 22 . Consistent with this observation, miR204 was readily detectable in INS1 cells, but in agreement with the results from the other microRNAs, its expres sion was even higher in primary human islets, whereas its expres sion in mouse islets was lower than in INS1 cells ( Supplementary  Fig. 1c ). Of note, human pancreatic islets are also one of the major sites of miR204 expression according to the microRNA.org website, Thioredoxininteracting protein regulates insulin transcription through microRNA204 l e t t e r S but the function and target genes of miR204 are unknown. Taken together, these findings suggest that miR204 might have an impor tant role in betacell biology, and we therefore decided to focus on this microRNA.
Using quantitative realtime RTPCR (qRTPCR), we found that miR204 expression was over twofold higher in INSTXNIP cells as compared to its expression in control INSLacZ cells (Fig. 1a) , confirming our microarray findings. In contrast, primary islets from Txnipdeficient HcB19 mice (which harbor a natural nonsense muta tion in the Txnip gene) showed significantly lower miR204 expres sion as compared to C3H control mice (Fig. 1b) . Similarly, miR204 expression was significantly lower in islets from our betacell-specific Txnip knockout (bTKO) mice as compared to lox/lox control mice (Fig. 1c) , further indicating that TXNIP regulates miR204 expression in beta cells in vivo.
Encoded within intron 6 of the TRPM3 gene (transient receptor potential melastatin 3, a cationselective channel), miR204 is tran scribed in the same direction as TRPM3 (ref. 23) . Because miR204 and TRPM3 therefore share the same promoter, we hypothesized that if TXNIP regulates miR204 expression at the transcriptional level, TRPM3 would be coregulated in parallel. Indeed, we found that Trpm3 expression was more than threefold higher in TXNIP overexpressing INSTXNIP cells as compared to its expression in control INSLacZ cells (Supplementary Fig. 1d ), whereas pri mary islets from Txnipdeficient HcB19 mice showed a significant (P < 0.05) reduction in Trpm3 expression (Supplementary Fig. 1e ). These findings are similar to results obtained for miR204 and suggest that TXNIP upregulates miR204 by inducing its transcription.
As TXNIP is not known to act as a transcription factor, we hypoth esized that it acts through the regulation of another factor. STAT3 was recently implicated in the downregulation of miR204 expres sion by some studies 4, 5 , and given the observed upregulation of miR204 in response to TXNIP, we investigated whether TXNIP might inhibit STAT3. Indeed, although TXNIP had no effect on Stat3 mRNA expression ( Supplementary Fig. 1g ) or total protein amounts, Stat3 phosphorylation and activation (which is crucial for STAT3mediated transcription) were substantially reduced in response to TXNIP (Fig. 1d) . Using STATTIC, a small molecule that selectively inhibits the activation of the STAT3 transcription factor by blocking its phos phorylation and dimerization, we investigated whether it could mimic the effects of TXNIP. We found that similarly to TXNIP, STATTIC significantly induced miR204 expression (Fig. 1e) , as well as that of its host gene, Trpm3 (Supplementary Fig. 1f ), suggesting that TXNIP confers its effects on miR204 at least in part through inhibition of STAT3.
Given the involvement of TXNIP in diabetes 3, 8, 24 , we investigated whether miR204 expression in beta cells might also be altered in diabetes. We used the wellestablished ob/ob mouse model, which is obese and diabetic as a result of leptin deficiency, in the C57/B6 background (B6 ob/ob) as a model of type 2 diabetes ( Supplementary  Fig. 2a,b) . Islets of obese and diabetic mice showed markedly elevated expression of Txnip (Supplementary Fig. 2c ). Most notably, miR204 expression was significantly higher in diabetic B6 ob/ob mice com pared to lean control mice (Fig. 1f) , suggesting that this microRNA might have a role in the betacell dysfunction of diabetes. Of note, we also found that miR204 expression was significantly (P < 0.05) ele vated in two additional models of diabetes: BTBR ob/ob and AZIP/F1 mice ( Supplementary Fig. 3a-f ). Unlike B6 ob/ob mice, which typi cally have rather mild diabetes, BTBR ob/ob mice are not able to compensate for their leptin deficiency-induced obesity and insulin resistance and develop severe type 2 diabetes that is consistent with a more pronounced islet phenotype that includes disrupted islet archi tecture and reduced wholepancreas insulin content 25 . In contrast, AZIP/F1 mice are not obese and lack white adipose tissue (because of adiposespecific transgenic expression of a dominantnegative pro tein (AZIP/F) that blocks C/EBP and Junmediated transcription) but are severely diabetic 26 . Despite these differences, both models showed higher Txnip expression, consistent with our previous findings 3, 8 , and higher miR204 levels compared to nondiabetic controls.
Given the proapoptotic effects of TXNIP, we also tested the pos sibility that miR204 might induce betacell apoptosis. However, compared to scrambled control microRNA, overexpression of miR204 did not result in a significant increase in the ratio of Bax to Bcl2 expres sion levels (P = 0.313), an increase in the amount of cleaved caspase3 or an increase in the number of TUNEL positive beta cells (data not shown), indicating that unlike TXNIP, miR204 does not induce beta cell apoptosis. We therefore tested how miR204 might affect other aspects of betacell function, such as insulin production.
Overexpression of miR204 in INS1 cells led to a >200% reduc tion in insulin mRNA expression (Fig. 2a) . Unlike humans, rodents have two insulin genes (Ins1 and Ins2), and although the data shown were obtained with primers detecting expression from both rat insulin genes, unless otherwise noted, primers specific for either Ins1 or Ins2 showed the same effect. In human islets, miR204 overexpression led to a similar decrease in insulin mRNA expression as in INS1 cells (Fig. 2b) , demonstrating that this effect is also relevant to human islet biology. In addition, the decrease in insulin mRNA expression translated into significantly reduced insulin content in miR204 overexpressing cells at the protein level (Fig. 2c) , as well as decreased insulin secretion (Fig. 2d ) and fractional insulin secretion ( Fig. 2e ; control insulin content was 7.5 and secretion was 1.7 ng ml −1 per µg DNA). The latter finding suggests that miR204 might have additional direct effects on insulin secretion. Moreover, the higher miR204 levels observed in the diabetic B6 ob/ob mice were also associated with significantly (P < 0.05) lower insulin gene expression ( Supplementary  Fig. 2d,e) . Similarly, elevated miR204 levels were also associated with reduced insulin gene expression in the two additional diabetes models tested, BTBR ob/ob and AZIP/F1 mice ( Supplementary Fig. 3a-f) .
In contrast, transfection of miR204 inhibitor oligonucleotides resulted in not only effective inhibition of miR204 ( Supplementary  Fig. 3g ) but also a significant (P < 0.05) increase in insulin mRNA expression ( Supplementary Fig. 3h ), suggesting that miR204 regu lates insulin gene expression. However, we observed that miR204 inhibited insulin promoter activity (Fig. 2f) rather than having the classical posttranscriptional effects of microRNAs on mRNA stability or translation. This suggests that the effect was indirect and was prob ably mediated by miR204-induced downregulation of factor(s) that are involved in insulin transcription.
To identify these factors, we next set out to find the putative gene targets of miR204, especially those that might have a role in insulin transcription. We therefore tested whether miR204 could inhibit the expression of any of the key insulin transcription factors, MAFA, MAFB, NEUROD or PDX1 (refs. [27] [28] [29] , which also came up as potential targets using miRWalk algorithms. Mafa mRNA and protein levels were markedly reduced in response to miR204 overexpres sion (Fig. 3a,b) , as well as in vivo in the context of diabetesinduced miR204 (Supplementary Fig. 2f ), whereas miR204 inhibition led to a more than twofold increase in Mafa expression ( Supplementary  Fig. 3i) . In contrast, the other transcription factors were not significantly altered by overexpression or inhibition of miR204 ( Supplementary Fig. 4a-f) .
Although MAFA has been shown to be capable of activating PDX1 promoter-driven reporter gene expression 30 , MAFA and PDX1 are not always coexpressed. Consistent with our findings, Mafa expres sion was previously found to be lower in islets from diabetic, obese, leptinreceptor mutant (db/db) mice compared to nondiabetic con trols and in response to cJun, whereas Pdx1 expression remained unchanged in these conditions 31 . In addition, glucose has been shown to induce the expression of Mafa but not Pdx1 in beta cells 32 . Here, we found that the miR204-induced reduction in Mafa expression also resulted in substantially reduced Mafa binding to the insulin promoter, as assessed by chromatin immunoprecipitation (ChIP) studies (Fig. 3c) .
Together these findings raise the possibility that MAFA acts as the miR204 target, mediating the effects of this microRNA on insulin gene expression. Comparison of the miR204 seed sequence and the rat Mafa 3′ untranslated region (UTR) revealed a perfect 7nt match (Fig. 3d) , suggesting that Mafa might be a target of miR204. To address this possibility, we generated reporter constructs with either a wildtype or mutated Mafa 3′ UTR (Fig. 3d) cloned down stream of the luciferase gene and assessed miR204-directed repres sion of the reporter gene. We found that miR204 significantly decreased luciferase activity through the wildtype Mafa 3′ UTR, whereas there was no reduction with the mutant 3′ UTR construct (Fig. 3e) , confirming that Mafa is indeed a direct target of miR204. Of note, MAFA is highly conserved across species at both the pro tein and mRNA levels, and TargetScan predicted that the rat 3′ UTR contains a unique miR204 binding site, which is consistent with our findings in rat INS1 beta cells. Furthermore, alignment of the rat, human and mouse 3′ UTR sequences revealed that six of the seven nucleotides contained in the miR204 seed match were also conserved in human and mouse MAFA (Supplementary Table 1) , and such matching has been reported to be sufficient for the downregulation of target messages 33 . Nevertheless, we also performed reporter assays using plasmids encoding the wildtype human MAFA 3′ UTR as well as a human MAFA 3′ UTR with a mutated miR204 binding seed sequence (Supplementary Fig. 4g ). The presence of miR204 led to a small but highly significant (P < 0.05) and consistent decrease in luciferase activity through the wildtype human MAFA 3′ UTR, and this effect was completely blunted by mutation of the seed sequence (Supplementary Fig. 4h) . Moreover, miR204 also significantly (P < 0.05) reduced MAFA expression in human islets ( Supplementary  Fig. 4i ) and led to an almost 50% reduction in human insulin expres sion (Fig. 2b) . This is in line with our findings in rat INS1 beta cells, demonstrates the translatability of the results and suggests that the miR204-MAFA-insulin pathway is also active in human islets.
It should be noted that currently, no validated human pancreatic beta cell line is available, making it necessary to use non-beta cell lines or primary human islets with a lower transfection efficiency, which may explain the slightly smaller effect size found in some of these experiments compared to those found using rodent models. Although even small changes in the expression of a transcription factor such as MAFA can lead to much larger effects on target gene expression (for example, insulin (as observed in our human islets)), we cannot exclude All data are shown as the mean ± s.e.m. of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t test). f npg l e t t e r S the possibility that additional factors targeted by miR204 might be involved in the more complex setting of the human islet.
To investigate whether TXNIP, as an upstream regulator of miR204, could mimic the effects of miR204 on MAFA, we analyzed our TXNIP overexpressing INS1 cell line and found a >200% reduction in Mafa mRNA expression and Mafa protein amounts (Fig. 4a,b) , similarly to what we observed in response to direct miR204 overexpression. In contrast, TXNIP had no effect on Pdx1, Mafb or Neurod expression (Supplementary Fig. 5a-c) . ChIP analysis revealed that Mafa occu pancy of the insulin promoter in the TXNIPoverexpressing cells was reduced to almost half of that in the INSLacZ control cells (Fig. 4c) . Moreover, TXNIP also reduced MAFA expression in human islets (Fig. 4d) , confirming the physiological relevance of these findings.
To further test whether TXNIP can block insulin production similarly to miR204, we conducted parallel experiments using our TXNIPoverexpressing INS1 cells, as well as human islets and Txnip deficient HcB19 mouse islets. TXNIP led to a significant decrease in insulin mRNA expression in the INS1 cells (Fig. 4e) and human islets (Fig. 4f) . This transient TXNIP overexpression in the human islets did not lead to any betacell apoptosis, as determined by an unchanged ratio of Bax to Bcl2 expression levels in the same samples, making any confounding effects in this regard extremely unlikely. At the protein level, TXNIP also caused a substantial reduction in insulin content (Fig. 4g) and an associated decrease in insulin secre tion (Fig. 4h) . This effect seemed to have been caused primarily by the reduced insulin content, as fractional insulin secretion was not significantly affected by TXNIP (Supplementary Fig. 5d ). In contrast, islets of Txnipdeficient mice showed a highly significant, twofold higher insulin content as compared to C3H control mice (Fig. 4i) , strongly supporting the notion that TXNIP inhibits betacell insulin production. To further obtain direct evidence for the role of miR 204 in this process, we overexpressed miR204 in islets of Txnip deficient mice, which completely blunted the effect of the lack of Txnip and reduced islet insulin content to amounts comparable with those in wildtype control mice (Fig. 4j) . This rescue experiment further established the causal relationship between decreased TXNIP and miR204 expression and increased insulin production and revealed an important functional link suggesting that TXNIP inhibits insulin production through the induction of miR204 expression. On the basis of our discovery that TXNIP inhibits STAT3 activation and STAT3 inhibition in turn increases miR204 expression, we also investigated the possibility that STAT3 inhibition could regulate insulin production. Both insulin and Mafa expression were significantly (P < 0.01) reduced in response to STAT3 inhibition ( Supplementary  Fig. 5e,f) , providing additional evidence for the importance of this newly identified pathway in conferring the observed effects of TXNIP.
Because miR204 and TRPM3 are coregulated by TXNIP, we addressed the question of whether any of the observed effects might be mediated by TRPM3. We therefore knocked down Trpm3 using siRNA and assessed whether this could mimic the effects of miR204 inhibition. However, although we found a robust downregulation of Trpm3 (Supplementary Fig. 5g ), the expression of neither Mafa (Supplementary Fig. 5h ) nor insulin ( Supplementary Fig. 5i ) was increased and, in contrast to the results of miR204 inhibition, were instead decreased. This result indicates that TRPM3 does not confer the observed TXNIPmediated inhibition of insulin transcription. Moreover, it also suggests that miR204 is able to not only regulate insulin transcription, as demonstrated by miR204 overexpression and inhibition, but, in the case of TXNIP overexpression, also out weigh the opposing effects of TRPM3.
Taken together, our findings in INS1 beta cells, islets of Txnip deficient mice, diabetic mouse models and primary human islets demonstrate that TXNIP inhibits STAT3 and induces betacell tran scription of a specific microRNA, miR204, which in turn blocks insulin production by directly targeting and downregulating the crucial transcription factor MAFA. This suggests that the TXNIPphosphorylated STAT3 (pSTAT3)-miR204-MAFA-insulin pathway may contribute to impaired insulin production, betacell dysfunction and the pathogenesis of diabetes (Supplementary Fig. 6 ).
Whereas our previous work revealed the important role of TXNIP in diabetic betacell death 2, 3, 8, 11 , our current results demonstrate that TXNIP also controls in vivo betacell function and insulin produc tion. The higher insulin production associated with TXNIP deficiency might have contributed to the antidiabetic effects observed 3 and may provide an added bonus when targeting TXNIP as a therapeutic approach for diabetes. Our current findings are also consistent with a previous report that showed an association of changes in TXNIP expression with altered insulin secretion 34 .
We previously found that Txnipdeficient HcB19 mice also have significantly (P < 0.05) lower blood glucose concentrations and are protected against streptozotocin and obesityinduced diabetes 3 . On the basis of the newly identified signaling pathway in which TXNIP induces miR204 expression and thereby downregulates MAFA and insulin production, one would anticipate that Mafa knockout mice would have a phenotype that is opposed to that of Txnipdeficient mice. Indeed, Mafa knockout mice are characterized by lower insulin transcription and higher blood glucose concentrations, and at ~1 year of age many Mafa knockout mice progress spontaneously to overt dia betes with blood glucose concentrations of over 500 mg dl −1 (ref. 35 ).
These data are not only consistent with our current findings but also underline the importance that this TXNIP-miR204-MAFA-insulin signaling cascade seems to have in the physiology and pathophysiol ogy of glucose homeostasis in a whole animal.
Because we discovered that TXNIP downregulates STAT3 phospho rylation and activation, which results in increased miR204 expres sion and decreased insulin production, STAT3 deletion would be predicted to impair glucose homeostasis. Indeed, pancreasspecific Stat3 knockout mice show glucose intolerance and impaired insulin secretion 36 , providing additional in vivo support for the new pathway we identified here.
Although multiple microRNAs have been implicated in betacell biology [15] [16] [17] [18] [19] [20] [21] and insulin gene expression 18,37-39 , miR204 has not been one of them. Nevertheless, in a study looking at microRNA patterns to distinguish between different pancreatic tumor types, miR204 was found to be highly expressed in insulinomas and to correlate with immunohistochemical expression of insulin 22 , which is commonly used as a marker to define the betacell origin of these tumors. In this context, it is also important to note that the high systemic concentra tions of insulin found in patients with insulinomas are due primarily to neoplastic growth and an abnormal increase in the number of insulin producing beta cells giving rise to the tumor and not necessarily to increased insulin production per beta cell. The observed correlation is therefore not able to provide any information about the regulation of insulin expression by miR204 and simply underlines the predomi nant betacell expression pattern of miR204 and, as stated by the authors of the previous study 22 , its potential usefulness in distinguish ing insulinomas from other pancreatic tumors. As such, their study is in line with our findings.
The discovery that miR204 is upregulated in diabetes and con trols insulin transcription reveals a potential new target for the future development of RNA therapeutics that would address an unmet need for increasing insulin production. Silencing of microRNAs has just begun to be explored for the treatment of cancers and various other diseases, including diabetes 40 . In addition, the observation that TXNIP controls microRNA expression, which can in turn regulate key tran scription factors such as MAFA and thereby perhaps modulate cell function and differentiation, fundamentally changes our understanding of the role TXNIP and microRNA biology have in health and disease.
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